✦ LIBER ✦

Controlled therapeutic trial of 1α-hydroxycholecalciferol in chronic renal failure

✍ Scribed by L. Tougaard; E. Sörensen; J. Bröchner-Mortensen; M. S. Christensen; P. Rödbro; A. W. S. Sörensen

Publisher: Springer
Year: 1976
Tongue: English
Weight: 161 KB
Volume: 22
Category: Article
ISSN: 1432-0827
DOI: 10.1007/bf02064048

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term trial of 1-alpha-hydroxycholec

Long-term trial of 1-alpha-hydroxycholecalciferol in adults with chronic renal failure

✍ S. Madsen; K. Ølgaard 📂 Article 📅 1978 🏛 Springer 🌐 English ⚖ 921 KB

Serum ionized calcium in renal failure —

Serum ionized calcium in renal failure — a guideline for 1α-hydroxycholecalciferol treatment

✍ S. Pors Nielsen; T. Falck Christiansen; M. Sanvig Christensen; E. Clausen; B. Kr 📂 Article 📅 1976 🏛 Springer 🌐 English ⚖ 404 KB

Placebo-controlled, double-blind, cross-

Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure

✍ A. C. S. Hokken-Koelega; T. Stijnen; S. M. P. F. Muinck Keizer-Schrama; J. M. Wi 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 119 KB

Phosphate binders for control of phospha

Phosphate binders for control of phosphate retention in chronic renal failure

✍ Mahmoud Loghman-Adham 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 52 KB

Failure of dietary protein and phosphate

Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial

✍ P. S. Williams; M. E. Stevens; G. Fass; L. Irons; J. M. Bone 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 112 KB

Efficacy of thymosin α1 in patients with

Efficacy of thymosin α1 in patients with chronic hepatitis B: A randomized, controlled trial

✍ Rong-Nan Chien; Yun-Fan Liaw; Tse-Ching Chen; Chau-Ting Yeh; I.-Shyan Sheen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 1 views

Thymosin ␣ 1 (T␣) is an immune modifier that has been shown in a pilot study to be effective for chronic hepatitis B; this requires confirmation. Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups: 1) group A received a 26-week course of T